Eterna Therapeutics INC 8-K filings

Ernexsa Therapeutics Inc. has released an updated investor presentation on July 2, 2026, providing new information and updates.

Ernexa Therapeutics Inc. reported the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Ernexa Therapeutics Inc. announced the resignation of Senior Vice President of Finance Sandra Gurrola, effective July 3, 2026.

Ernexia Therapeutics Inc. has filed a Form 8-K announcing a 1-for-25 reverse stock split of its common stock, effective May 4, 2026.

Ernexa Therapeutics Inc. received a Nasdaq delisting notice for failing to maintain a minimum bid price, complicated by a prior reverse stock split.

Ernexa Therapeutics Inc. announced the availability of an updated investor presentation, replacing a previous version from December 2025.

Ernexa Therapeutics Inc. announced the pricing of a public offering of common stock and warrants, expecting to raise approximately $10.5 million in gross proceeds.

Ernexa Therapeutics Inc. announced the availability of a new investor presentation, accessible on its website and filed as an exhibit to its latest 8-K.

Ernexa Therapeutics Inc. has dismissed Grant Thornton LLP and appointed Haskell & White LLP as its new independent registered public accounting firm, following previous audit reports that included a going concern explanatory paragraph and a disclosed material weakness in internal controls.

Ernexa Therapeutics Inc. has announced a 1-for-15 reverse stock split of its common stock, effective June 12, 2025, aimed at increasing its per-share trading price.

Ernexa Therapeutics Inc. announced the successful completion of the second closing of its private placement, raising approximately $6.0 million, bringing total proceeds to $7.0 million, and enabling the company to regain compliance with Nasdaq's continued listing requirements.

Ernexa Therapeutics Inc. stockholders approved a reverse stock split, an increase in authorized common shares, and the potential issuance of over 20% of outstanding stock, alongside re-electing directors and ratifying corporate governance matters at their 2025 Annual Meeting.

Ernexa Therapeutics secures $7.3 million through a private placement of common stock and pre-funded warrants to accredited investors, aiming to strengthen its working capital.

Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., officially changed its name and adopted amended bylaws effective March 26, 2025.

Eterna Therapeutics Inc. has entered into a promissory note agreement for $750,000 with Charles Cherington, a significant shareholder, to bolster its financial position.

Eterna Therapeutics Inc. has entered into a promissory note agreement for $1.5 million with Charles Cherington, bearing a 5% interest rate.

Eterna Therapeutics announces the date for its 2025 annual meeting of stockholders and deadlines for stockholder nominations and proposals.

Eterna Therapeutics received a Nasdaq notice regarding its Market Value of Listed Securities falling below the required minimum and appointed Dr. Elena Ratner to its Board of Directors.

Eterna Therapeutics has received a notice from Nasdaq for failing to maintain a minimum share price of $1, triggering a compliance period to avoid delisting.

Eterna Therapeutics finalized a private placement of common stock and restructured its debt, while also preparing for a Nasdaq hearing to address listing compliance.

Eterna Therapeutics has entered into a new exclusive license and collaboration agreement with Factor Bioscience, replacing previous agreements and securing rights to develop technology in cancer, autoimmune disorders, and rare diseases.

Eterna Therapeutics has entered into agreements for a $3.9 million convertible note offering and a $1.1 million private placement of common stock, alongside exchange agreements to restructure existing debt and warrants.

Eterna Therapeutics has received a notice from Nasdaq stating that it did not meet the terms of its extension to regain compliance with the minimum stockholders' equity rule, potentially leading to delisting.

Eterna Therapeutics has scheduled its 2024 annual meeting for September 27, 2024, and set an August 29, 2024 deadline for stockholder proposals and director nominations.

Eterna Therapeutics has received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement, placing its listing status at risk.

Eterna Therapeutics has appointed Peter Cicala as an independent director to its Board, effective February 12, 2024.

Eterna Therapeutics received a notice from Nasdaq stating that the company no longer complies with the exchange's majority independent board and independent audit committee requirements.